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Abstract: 
Abdominal aortic aneurysm is a major health concern and may be associated with high rates 
of mortality linked to acute complications. Diagnosis and treatment are respectively based on 
imaging and surgical techniques. Drug-based therapies are still mostly ineffective, which 
highlights a real unmet need. Major pathophysiological mechanisms leading to aneurysm 
formation involve inflammatory processes, degradation of the extracellular matrix, and loss of 
smooth muscle cells. However, the precise cellular and molecular pathways are still poorly 
understood. Recently, microRNAs have emerged as major intracellular players in a wide 
range of biological processes, and their stability in extracellular medium within microvesicles 
has led to propose them as mediators of intercellular crosstalk and as potential biomarkers and 
therapeutic targets in a variety of disease settings. To date, several studies have been 
performed to address the involvement of micro-RNAs in aneurysm formation and 
complications. Here we discuss the roles and implications of micro-RNAs in animal models 
and their relevance to human abdominal aortic aneurysm. 
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Abbreviations: 
AAA: abdominal aortic aneurysm 
angiotensin II/ apoE-/-: angiotensin II infusion into apolipoprotein E deficient mice  
ATLOs : adventitial tertiary lymphoid organs  
BLT1: Receptors for leukotriene B4 
Chi3l1: chitinase 3-like 1 
CTLA4: cytotoxic T-lymphocyte-associated protein 4 
ECM: extracellular matrix  
IL-3: interleukin-3 
miR: micro-RNA 
mRNA: messenger RNA 
MMP: metalloproteinase  
CVR-2015-1140R1 
 
3 
 
PAD: peripheral arterial disease 
PTEN: phosphatase and tensin homolog 
RECK: reversion-inducing cysteine-rich protein with kazal motifs 
TAA: thoracic aortic aneurysm 
TIMP3: tissue inhibitor of metalloproteinase 3 
VEGFA: vascular endothelial growth factor A 
VSMCs: vascular smooth muscle cells 
 
Introduction 
Abdominal aortic aneurysm (AAA) is defined as a focal dilatation of the aorta. Affecting up 
to 8% of men 1 and 1.3% of women over 65 years old 2, the disease is often asymptomatic but 
may become life threatening, especially when revealed by an acute rupture 3. Epidemiological 
studies highlight the frequent association of AAA with atherosclerosis and some 
corresponding risk factors 1, 4, 5. However, the mechanisms underlying AAA formation and 
progression may differ, particularly with regard to the degree of vascular remodeling in the 
media layer, and are not completely understood. AAA formation results from a complex 
process involving vascular and immune cell subsets 6. Pathological features include 
adventitial and medial inflammatory cell infiltration associated with a degradation of 
extracellular matrix (ECM) components, including elastin and collagen, by an array of 
proteases such as matrix metalloproteinases (MMPs). Impairment of vascular smooth muscle 
cells (VSMCs) homeostasis favours their (de)differentiation to a secretory phenotype with 
alteration of migratory, proliferative and survival functions, which may significantly impact 
vascular remodelling and weaken the aortic wall. Additional alterations of endothelial cell 
function and formation of an intraluminal thrombus most probably contribute to pathologic 
aortic wall remodelling and disease progression.  
Over the past decades, micro-RNAs (miRs) have emerged as major post-transcriptional 
regulators of gene expression 7 and have been shown to play key roles in vascular biology and 
cardiovascular diseases 8-10. In this context, clinical and experimental studies have been 
performed to better understand the implications of miRs in AAA pathophysiology.  
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The aim of our review is to discuss the interest, limits and relevance of models to investigate 
the roles of miRs in AAA. 
 
Human studies 
Clinical relevance  
The treatment of AAA is currently based on surgical intervention as no drug has proven yet 
enough benefit. In practice, the decision to treat relies on a balance between the risk of 
progression or rupture and the operative risks 4, 5. However, despite the identification of some 
risk factors (e.g., large aneurysm diameter, high growth rate, association with female gender, 
smoking or hypertension), the risk of progression and rupture can still be difficult to predict. 
While some biomarkers have been reported to be associated with AAA, none of them has 
proven enough sensitivity or specificity to be used in daily medical practice 11, 12. Thus, a real 
need emerged to develop new tools and help clinicians evaluate the risk of progression, 
rupture and post-therapeutic outcomes. 
 
miRs as potential biomarkers of AAA (Table 1)  
In that context, several clinical studies have been set up to identify new biomarkers of AAA 
(Table 1). The first landmark supporting the idea that miRs could reflect the disease was the 
observation of a differential miR expression in aneurysmal tissue compared to intact aortic 
samples. Indeed, some were found upregulated in aneurysmal tissue (miR-21 13-15, miR-205, 
378 14, miR-126, 20a, 27a, 92a, 221, 222, let-7f, 155, 146a, 223, 124a 15), others down 
regulated (miR-133a, 331-3p, 30c-2*, 204 16, 24, 27b 17), whereas some (miR-133b, 29b) 
appeared either increased or decreased 14-16, 18.  Note that the differentially expressed miRs 
substantially varied between studies. In a few cases, a similar variation of expression was 
observed for miR-21 and miR-155 in aneurysmal aortic tissue compared to their proper 
controls 13-15, 19. In contrast, divergent results were found for miR-29b and miR-133b 14-16, 18, 
which could be partly explained by differences in methodologies used, including patient 
population, stage of the disease and technical approaches. While most of the above studies 
compared miR expression in aorta between patients with or without AAA, one study 
investigated miR expression in aortic samples exclusively from patients with AAA 19. 
Interestingly, the authors found that the composition and the expression of miRs is different 
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between aortic tissue obtained from the body (at the site of maximum AAA dilatation) and the 
neck (defined as macroscopically non-dilated aorta), revealing a variation of miR expression 
within the aneurysmal tissue itself. 
In contrast, some investigators studied miR expression in some specific structures present in 
AAA such as adventitial tertiary lymphoid organs (ATLOs) 20. As ATLOs are mainly 
composed of immune cell subsets 21, it is not surprising that the authors observed a 
differential miR expression in ATLOs compared to VSMCs from non-aneurysmal aorta. 
Although ATLOs appear to play a role in atherosclerosis and AAA development, they are not 
systematically observed in atherosclerotic and aneurysmal tissues 20, 22. Hence, miR 
expression could reflect the presence of ATLOs and inflammatory processes occurring within 
adventitial layer during AAA. Besides, these results suggest that cell specific miR expression 
should be analysed in order to fully understand their role. In another study, some authors 
addressed this question and found a differential expression of miR-516a-5p and miR-1260 in 
VSMCs cultured from AAA tissue as compared to VSMCs from non-aneurismal aortas 23. 
While the observation of a deregulated miR expression profile in aortic tissue and specific cell 
subsets during AAA offers perspective to identify new biomarkers of the disease, their 
potential use in clinical practice is hardly possible using aortic samples as they can only be 
collected by invasive procedures. The discovery of circulating miRs in different biological 
fluids, has led to propose them as non-invasive biomarkers in a wide range of pathologies 
including cardiovascular diseases 24. Interestingly, a differential miR expression was observed 
between patients with AAA and controls, both in whole blood 25 and in plasma 17, 25-27. 
Some investigators also found a differential miR expression in plasma (miR-15a-3p, 30a-5p) 
and in serum (miR-155) between patients with AAA and patients with peripheral arterial 
disease (PAD) 19, 20, suggesting that circulating miRs may display distinct patterns in AAA 
compared to other cardiovascular diseases. However, in another study investigating other 
miRs, no difference in miR profile could be detected between patients with AAA and PAD 25, 
suggesting that changes in the expression of some miRs could be linked to a common 
pathological process such as atherosclerosis. The identification of similar miR patterns in 
distinct cardiovascular diseases underlines the need to test their specificity for a potential use 
in medical practice. Addressing this question in a cohort of 120 individuals, some 
investigators found that for 3 miRs (miR-191-3p, 455-3p, 1281) investigated, the sensitivity 
to diagnose AAA varied from 76.7% to 95% and the specificity from 96.7% to 100% 26. Even 
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if further investigations are required on larger cohorts, the results are encouraging and may 
lead to the validation of reliable biomarkers of AAA. Furthermore, circulating miRs could be 
potential biomarkers of AAA growth, as suggested by the association between aortic diameter 
and plasma levels of miR-340, 20a, 148a, 125b, 195 27.  
However, only a few studies identified the same disease-related miRs in peripheral blood and 
results were heterogeneous, as demonstrated by divergent circulating levels for miR-15515, 19 
and miR-29b 15, 25. The observed difference could be partly explained by the nature of the 
blood sample used, as the expression of some miRs can vary between plasma and serum 28.  
Additional points need also to be more deeply investigated. First, the origin of circulating 
miRs is not totally elucidated. According to the current knowledge, they could derive from 
cellular degradation and/or be released through various modes of vesiculation (e.g., 
microparticles or exosomes) 29. Besides, circulating miRs measured in blood could come from 
a wide range of tissues and cell subsets. Even if some miRs misexpressed in aortic samples 
were also deregulated in the circulation such as miR-20a 15, 27, miR-155 15, 19, miR-29b 15, 18, 
and miR-124a, 223, 126, 146a 15, the pathways responsible for their deregulation in aortic 
samples and blood need to be further investigated and potential links identified. Also, the role 
of differentially expressed miRs remains to be established in order to better appreciate their 
relevance as biomarkers or causal factors in AAA pathophysiology. 
 
Roles of miRs in the pathophysiology of human AAA  
Intracellular miRs mainly regulate gene expression through binding to their target messenger 
RNA (mRNA), inhibiting their translation or inducing their degradation 7. Several studies 
identified predicted targets of deregulated miRs using bioinformatics approach and many of 
them appear to be involved in biological pathways relevant to AAA development such as 
inflammation, ECM remodelling, apoptosis or cell proliferation 16, 23, 25. 
Some investigators provided direct in vitro experimental evidence for regulation of the 
theoretical targets by the identified miRs, and further addressed gene expression or protein 
levels of the potential miR targets in vivo. Interestingly, a correlation was found between 
some deregulated miRs in aneurysmal aorta and expression of their putative targets involved 
in inflammation, as demonstrated by the opposite variation between miR-155 and cytotoxic T-
lymphocyte-associated protein 4 (CTLA4) expression 19, miR-24 and chitinase 3 like 1 
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(Chi3l1) 17, miR-146a, 124, 223, 126 and inflammatory cytokines 15 or miR-516-5p and levels 
of IL-3 and VEGFA secreted by VSMCs 23. Besides, several studies observed a decrease of 
some miRs (miR-1260, 29b) in aneurysmal aorta, in association with significant changes in 
protein or gene expression of ECM components such as collagen 18, 23. Thus, clinical studies 
revealed concomitant deregulation of some miRs and their putative targets, some of them 
being key-players in mechanisms involved in AAA formation, including inflammation, 
fibrosis or ECM remodelling, suggesting potentially causal roles of miRs in the 
pathophysiology of human AAA. 
 
Limits of clinical studies 
Clinical studies have highlighted the potential implication of miR-regulated processes in the 
pathophysiology of AAA. However, comparison of the results among different studies reveals 
a low overlap of differentially regulated miRs. Thus, several considerations should be taken 
into account when designing clinical studies in order to minimize potential bias in data 
collection, analysis and interpretation. 
The first point relates to the population studied and the inclusion criteria. Pathophysiological 
characteristics including age, sex, presence of comorbidities or associated cardiovascular risk 
factors may impact on miR expression 30-33 and act as confounding elements. Such factors 
should be clearly identified and controlled for during study design and in the final statistical 
analysis. 
Additional considerations relate to sample collection. First, human aortic tissue can only be 
collected from patients who undergo a surgical intervention and as a consequence, analysis of 
aortic miR expression was most often performed on small cohorts. Obtaining proper aortic 
controls can even be more challenging. Studies used aortic samples from different origin: 1) 
patients undergoing liver transplantation or surgical valve repair 15, 23, 2) organ-donors 13, 17, 18, 
20, 3) cadaveric donors 16, 25. However, although miRs are highly stable in both tissues and 
biological fluids 34, 35, their stability in post-mortem conditions is not well known 36. While in 
the majority of studies aortic control samples were taken from the abdominal aorta, one study 
obtained samples from the ascending aorta 15. Note that in physiological conditions, thoracic 
and abdominal aortas are subjected to different hemodynamic loads, differ in histological and 
biochemical composition, and in the embryologic origin of their VSMCs 37, 38. In pathological 
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setting, AAA and thoracic aortic aneurysm (TAA) are characterized by distinct 
epidemiological patterns and aetiological factors 39. While a few miRs deregulated in AAA 
such as miR-21, miR-29b, and miR-133a were also differentially expressed in TAA compared 
to controls 13-15, 18, 40-43, specific miRs other than those identified in AAA could be identified 
in TAA, including differential expression of miR-1, 29a, 143, 145, and 486-5p 40-42, 44. As 
such, it is highly plausible that the pattern of miR expression may differ between abdominal 
and thoracic aorta, both in health and disease. Thus, appropriate control samples should come 
from the same aortic region. In other studies, some investigators did not collect aortic samples 
from patients without AAA and made direct comparisons between miRs expressed in AAA 
body and in neck 19. The use of the neck as control to study miR expression presents the 
advantage to be perfectly matched with the samples obtained from the body of the AAA. 
However, histological analysis revealed that even if biopsies from the neck show relative 
preservation of intimal and medial structures, the morphology is not completely normal, as 
demonstrated by inflammatory cells infiltrated in the adventitial layer 45. As a consequence, it 
is possible that miR expression in the neck of AAA differ from intact non aneurysmal aorta.  
Compared to aortic tissues, blood samples have the advantage to be easier to collect, allowing 
to study larger cohorts of patients with AAA. Nevertheless, circulating miR profile may differ 
depending on the nature of the sample 28 and can be altered by treatments commonly 
prescribed to patients with AAA such as anticoagulants, antiplatelets 46, antidiabetic agents 47, 
or cholesterol lowering drugs 48. Also, the numerous methods used for miR detection and data 
normalization can potentially impact on miR profile 49, 50. 
As a conclusion, clinical studies on miRs in AAA offer interesting opportunities to explore 
their potential use as biomarkers and to study their role in AAA pathophysiology. However, 
the methodology used differed between the studies, making difficult any direct comparison 
between the results. Besides, clinical studies present several limitations in addressing the 
precise cellular and molecular effects of miRs in AAA development. First, aortic samples can 
only be taken from patients who have surgical indication, which means that they have 
advanced or complicated lesions. This is a major limitation to the study of the role of miRs in 
the early stages of AAA development. Second, while some correlations between miRs and 
their putative targets have been identified, it is difficult to determine if miR deregulation has a 
causal effect on AAA development, or on the contrary results from a compensatory 
mechanism to regulate it. Hence, the need to use animal models, which allow detailed 
mechanistic approaches to the disease process. 
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Animal studies 
Animal models of AAA used to study miRs  
Several experimental models of AAA have been developed over the past decades including 
genetic, surgical and chemically induced models in rodents or larger animals 51-53. Surgical 
models directly induce mechanical injury within the arterial wall leading to AAA but require 
technically difficult procedures and expose the animals to prolonged anaesthesia. In that 
context, due to their efficiency to induce AAA, their relative technical simplicity and low 
cost, studies on miRs have been exclusively performed on chemically induced AAA in 
rodents (Table 2). 
Angiotensin II infusion into apolipoprotein E deficient mice (angiotensin II/ apoE-/-) has 
been, to date, the model the most commonly used to study miRs in AAA 13, 14, 17, 18, 27, 54. This 
model usually induces AAA located in the suprarenal aorta within 28 days and reproduces 
some of the major features observed in AAA pathophysiology such as medial degradation 
with ECM remodelling, inflammation and association with atherosclerosis 55, 56. While 
hyperlipidaemia increases incidence, it is not required for the induction of AAA. As a 
consequence, some investigators used angiotensin II infusion in C57BL/6 mice 43. Another 
commonly used chemically induced model of AAA is the elastase perfusion model. The 
technique requires a surgical intervention to introduce a catheter in the infrarenal aorta and 
perfuse pancreatic porcine elastase for 5 to 15 minutes 57. The perfusion of elastase induces a 
destruction of medial elastic tissue and inflammation, leading to infrarenal AAA formation 
within 14 days 58. At last, some investigators used a third model in rats, consisting in 
application of calcium chloride in combination with collagenase on the adventitial layer of the 
aorta between the renal branches and the iliac bifurcation 59. Calcium chloride application 
provokes calcium deposition throughout the media, disruption of ECM and induction of 
inflammatory responses, leading to infrarenal AAA development between 2 or 4 weeks 60. 
 
Roles of miRs in AAA pathophysiology and as therapeutic tools 
The studies performed so far in animal models have provided interesting results. First, 
differential miR expression between aneurysmal and control aorta was observed in all the 
models described above 13, 14, 17, 18, 27, 43, 54, 59. Furthermore, several studies reported inverse 
CVR-2015-1140R1 
 
10 
 
correlations between miR levels and the expression of their putative targets, involved in key 
mechanisms of AAA pathophysiology. As an example, miR-29b expression was decreased in 
aneurysmal aortic wall and negatively correlated with collagen and elastin gene expression 18, 
which strongly suggested a role of miR-29b in ECM remodelling. In another study, a decrease 
of miR-24 was observed concomitantly with an increase of its putative target Chi3l1, 
pinpointing the potential role of miR-24 in inflammation 17. Similarly, a decrease of miR-26a 
in aneurysmal aortic tissue was reported to occur in parallel to an increase of several predicted 
targets, including genes involved in cell cycling, apoptosis, proliferation, migration or 
cytokine production 54.  
While correlation between miR expression and their predicted targets can be studied in both 
human and animal models, animal studies offer the great possibility to modulate miR 
expression and study its direct impact on the disease process. miR modulation consists in 
overexpressing a miR using a miR-mimic or inhibiting its expression with an antago-miR. 
miR-mimics are double stranded oligonucleotides in which one of the strand is the mature 
miR sequence. In the cell, miR biogenesis machinery recognizes the miR-mimic and 
processes it, delivering the mature miR strand and leading to its overexpression 61. In contrast, 
antago-miRs are synthetic single-stranded RNA analogues complementary to miRs, which 
hybridize specifically with the target miR, inhibiting its effect 62. 
Modulating miR expression allows for better understanding of their roles. Several studies 
highlighted the potential contribution of miRs to AAA development. As an example, miR-712 
and its homolog miR-205 were increased concomitantly with: 1) a decrease of two MMP 
inhibitors TIMP3 (tissue inhibitor of metalloproteinase 3) and RECK (Reversion-inducing 
cysteine-rich protein with kazal motifs), and 2) an increase of MMP activity in the abdominal 
aortic endothelium of angiotensin II-treated apoE-/- mice compared to controls 14. Silencing 
miR-712 or miR-205 reversed the downregulation of TIMP3 and RECK, decreased MMP 
activity and elastin fragmentation, preventing AAA formation. Hence, miR-712 and miR-205 
misexpression seems to play a causal effect in aortic endothelium promoting AAA 
progression through targeting key molecules involved in ECM remodelling. 
Another study found a decrease of miR-24 in AAA tissue compared to non-diseased aorta, 
both in the elastase and angiotensin II/ apoE-/- models 17. In the elastase model, miR-24 
inhibition using intraperitoneal injection of lenti-anti-miR-24 increased aortic dilatation and 
incidence of rupture, concomitantly with an increase of Chi3l1. In contrast, miR-24 
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overexpression using a lenti-premiR-24 injection revealed opposite effects on Chi3l1 
expression, decreased macrophage infiltration and attenuated AAA dilatation. Similar results 
were found in angiotensin II/ apoE-/- model, suggesting that miR-24 contributes to AAA 
development through the regulation of inflammatory processes via targeting Chi3l1. 
While the above studies revealed a contributing role of some miRs to AAA formation, others 
have suggested protective or compensatory roles for a few miRs. For example, miR-29b 
expression was decreased in infrarenal aortic tissue of both elastase and angiotensin II/ apoE-
/- models, concomitantly with an increase of collagen and elastin 18. Further inhibition of 
miR-29b through anti-miR-29b injection boosted the increase of collagen and elastin gene 
expression resulting in a significant reduction of AAA expansion. Another study corroborated 
this finding and reported a decrease of aortic diameter and enhanced survival after systemic 
inhibition of miR-29b in angiotensin II/ apoE-/- mice 27. Overexpressing miR-29b through 
administration of premiR-29b showed opposite effects, increasing AAA development 18. 
These results indicate that the decrease of miR-29b observed in aortic tissue may result from a 
compensatory mechanism to counter-regulate AAA expansion. In another study, miR-21 was 
found increased in AAA tissue of elastase and angiotensin II/ apoE-/- models 13. miR-21 
overexpression increased cell proliferation and decreased apoptosis in the aortic wall, 
associated with a reduction of PTEN protein (phosphatase and tensin homolog) and activation 
of AKT which led to protection against AAA expansion. In contrast, antago-miR-21 injection 
increased PTEN expression and promoted AAA growth. Hence, miR-21 upregulation 
observed in AAA tissue appears to be a physiological response elicited to counter-regulate 
and prevent AAA expansion.  
Thus, several miRs have been identified as causally linked to the development and 
complication of AAA in animal models, offering the perspective to use miRs as therapeutic 
tools and targets. Nevertheless, further studies in animal models need to be performed before 
potential applications can be translated to the clinical arena. First, the sustainability of the 
biological effect of miR modulation needs to be further investigated as several studies 
observed a steady decrease of the biological effect during the 28-day follow up period 13, 18. 
Second, the delivery and uptake of miR modulators need to be well characterized in order to 
improve selective targeting and limit potential side effects. Analysis of aortic localisation and 
effects of some miR modulators after systemic injection suggested that they were almost 
exclusively limited to the site of injury in the elastase model 13, 17, 18. However, their uptake in 
the aortic wall in other AAA models needs to be further characterized. Systemic 
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administration of some miR modulators of miR-29b or miR-21 was associated with biological 
effects in other organs such as the heart, the liver or the kidney 13, 18, 27, which may induce 
substantial side effects. Hence, local administration could be a step forward to limit 
undesirable effects. Interestingly, some investigators studied in vivo local inhibition of some 
miRs using an aortic isograft model 27. The technique consists in harvesting the aorta, 
incubating it with miR modulators, then re-implanting it into the carotid artery of recipient 
mice. While the technique resulted in effective local modulation of miR expression, it can’t be 
extrapolated for a potential use as therapeutic tool in patients as it requires aortic tissue 
removal and re-implantation. In practice, surgical intervention physically excludes the 
aneurysm using a synthetic prosthesis 4, 5. Thus, investigating local modulation of miR 
expression through drug administration via the prosthesis would be of great interest. To date, 
experiments using stent grafts for surgical repair of AAA have been mostly performed on big 
animals such as dogs and pigs given the larger size of the aorta 63, 64. Nevertheless, graft 
implantation in smaller animals like rats has been developed 65 and performed in animals with 
induced AAA 66. In this context, a recent study addressed the feasibility of local miR 
modulation using an anti-miR-21-coated stent 67. To investigate the role of miRs in in-stent 
restenosis, the authors used a model in which balloon-injured and stented human internal 
mammary arteries were anastomosed to the abdominal aorta of Rowett nude rats. 
Interestingly, anti-miR-21–coated stents reduced in-stent restenosis compared to bare metal 
stents and screening for off-target effects did not reveal any miR-21 expression changes in 
kidney, liver, heart, or lung. Hence, stent graft implantation in murine models as well as the 
development of stents coated with miR modulators offer great perspectives for the testing and 
translation of miR-based therapeutic strategies to combat AAA. 
 
Impact of risk factors on miRs and consequences for AAA development 
While in human studies presence of associated risk factors may potentially confound results 
interpretation, animal studies offer the advantage of a homogeneous background and the 
possibility to investigate the contribution of individual risk factors to miR expression and 
AAA development. Among the risk factors of AAA, smoking is considered as one of the most 
important 4, 5. As previously mentioned, miR-21 expression is increased in the aneurysmal 
aortic segments of both elastase and angiotensin II mouse models 13. Interestingly, 
subcutaneous nicotine administration during 60 days boosted the increase of miR-21 in both 
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models. The overall results of the study suggested that miR-21 upregulation was a 
physiological protective response to prevent AAA expansion. 
The impact of aging has also been addressed. Investigators reported an increase of miR-29b 
expression in aortic tissue of aged compared to young mice 43. miR-29b expression is 
decreased in the aneurysmal aorta of both elastase and angiotensin II/ apoE-/- models, and its 
downregulation seems to play a protective role on AAA formation 18. Interestingly, an 
increase of miR-29b expression was observed in the aneurysmal aorta of aged wild type mice 
infused with angiotensin II 43. Further, inhibition of miR-29b expression in this model 
prevented the increase of aortic diameter induced by angiotensin II. These results suggest that 
down regulation of miR-29b could result from a physiological response to prevent AAA 
expansion, and that aging could, at least partly, contribute to AAA development through an 
impairment of that mechanism. Hence, animal models offer the possibility to better 
understand the direct roles of miRs and the molecular mechanisms that link risk factors 
identified in epidemiological studies to AAA development. 
 
miRs in other forms of aortic aneurysm 
Aortic aneurysm may also involve the thoracic aorta. TAA develop frequently at younger 
ages, and are often linked to hereditary influence and display distinct pathological features 
compared to AAA39. Only a few studies investigated miR expression in animal models of 
TAA: fibulin-4R/R knockdown and Fbn1 (C1039G/+) Marfan mouse model 43, 68. miRs 
differentially expressed within the aneurysmal aortic wall during TAA differed from those 
identified in AAA, as demonstrated by changes in expression of miR-29a and miR-29c in 
TAA, whereas no variation was observed for miR-21 43, 68. In contrast to AAA animal models, 
miR-29b expression was found increased in thoracic aneurysmal aortas 43, 68, and played a 
causal role as demonstrated by the prevention of early aneurysm development induced after 
blockade of miR-29b in Marfan mice 68.  
 
Relevance of animal models of AAA 
Animal models provide interesting opportunities to study miRs in AAA. However, it is 
necessary to identify the potential confounding factors that may alter miR expression profile 
and downstream miR effects in each model. For example, hypertension, which develops in 
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response to infusion of angiotensin II 69 may be associated with modification of miR 
expression in the aorta 70 and may therefore account, at least in part, for changes of miR 
profile observed in angiotensin II-infused mice. The use of apoE-/- mice, which develop 
hypercholesterolemia and atherosclerosic lesions 71 may also be a confounding factor given 
the potential direct impact of atherosclerotic changes on miR expression profile in the aortic 
wall 72. Thus, data reproducibility between different animal models of AAA is worth of 
evaluation. 
A few studies investigated the same miRs in different models of AAA. Interestingly, 
consistent results of miR expression in aneurysmal aorta were found between different models 
for miR-21 and miR-29b 13, 14, 18, 54 and their effects on the disease process were reproducible 
13, 18. Note that while a decrease of miR-29b was observed in aortic tissue in both elastase and 
angiotensin II/ apoE-/- models 18, one study reported an increase of its expression in the aorta 
of 18-month wild type C57BL/6 mice infused with angiotensin II 43. However, that difference 
may be attributed to the impact of aging on the aorta. The concordance of results between 
different animal models suggests that the identified miRs are strongly linked to the 
pathophysiology of AAA, and less to the direct effect of AAA-inducing agents or to the 
presence of associated disease states such as hypertension, hypercholesterolemia or 
atherosclerosis. Nevertheless, it is possible that divergences between animal models are 
underestimated due to the fact that inconsistent results among different models in the same 
study are less likely to be published.  
The relevance of animal models to human AAA pathophysiology also needs to be addressed.  
The mouse models described above all reproduce some of the human features of AAA such as 
higher incidence in males than in females. They also mimic some of the histological 
characteristics of human lesions including medial degradation, ECM remodelling, and 
inflammatory responses 55, 58, 60. However, each model has its own specificities, which may 
make it differ from the human disease.  
Infusion of angiotensin II in ApoE-/- is associated with the development of atherosclerosis, 
hypertension and hypercholesterolemia, which are risk factors frequently identified in human 
AAA 4, 5. Death related to aortic ruptures can be observed in the model 73, allowing to study 
the mechanism leading to this complication. Nevertheless, aneurysm formation tends to occur 
in the suprarenal aorta, while the most frequent location of AAA in humans is infrarenal. In 
addition, rupture observed in that animal model is favoured by the rapid development of 
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medial dissection associated with the formation of transmural thrombi and haematomas 73, 74 
In human AAA, medial dissection is not common, in contrast to rupture, and thrombi usually 
appear in the intraluminal part of the aorta 75. Compared to angiotensin II infusion, elastase 
perfusion model has the advantage to directly induce AAA in the infrarenal aorta 57, 58. 
However, incidence of rupture is rare. The calcium chloride model does not lead to thrombus 
formation or rupture, which are major features of the human disease. 
Dissimilarities of each of the models with the human disease may question the translational 
relevance of the results obtained in mice. Interestingly, some miRs identified in animal studies 
were also observed to be dysregulated in humans (Table 2). This is for example the case of 
miR-21 13-15, 54, mir-221, miR-146a and miR-222 15, 59, miR-24 17, or miR-205 14 which were 
similarly modulated in aneurysmal tissue of mice and humans. 
However, the expression of other miRs revealed more heterogeneous results. This was the 
case for miR-133b, which was increased in endothelial cells of murine aneurysmal aorta 14, 
but was reported to be either increased 14 or decreased 16 in human aneurysmal aorta 
compared to normal aortic tissue. Note that in the animal study, investigators only used the 
endothelial part of the aorta, while in both human studies the whole wall tissue was processed 
to extract RNAs. Heterogeneous results were also found for miR-29b, which was decreased in 
two different animal models 18, while its expression was either decreased 18 or increased 15 in 
human aneurysmal aorta. miR-195 was increased in the aorta of angiotensin II/ apoE-/- mice, 
but when its circulating level was investigated in human plasma, an inverse association was 
found between miR-195 and the presence of AAA 27. Note that the origin of the biological 
samples used to determine miR-195 expression differed, which may explain the opposite 
variation of this miR between mice and humans. 
Thus, even if animal models are useful to study the role of miRs in AAA development, 
dissimilarities of expression were found for some miRs between humans and animals, which 
can be attributed to differences in methodology and/or pathophysiological features. Moreover, 
even if miRs are well conserved, their regulation may differ among species, which may 
account for some of the observed differences 76.  
 
Future directions 
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We believe that a few issues should be taken into account in future work. Most studies 
addressed the expression of a limited number of miRs and followed a hypothesis-driven 
approach. As changes in miRs do not occur in isolation, it should be useful to follow, at least 
in pilot studies, an unbiased discovery-driven approach looking at all existing miRs with the 
aim to account for the formidable complexity of the disease and try to identify novel miR 
signatures (combinations of miRs). This may not only improve the sensitivity and specificity 
of circulating miRs as potential biomarkers of AAA but may also inform about the de-
regulation of selective and previously unsuspected biological pathways involved in the 
disease. 
In both clinical and experimental studies addressing vascular miR expression, the role of 
miRs was mainly investigated in whole aortic tissue samples. To fully understand their 
complex role in AAA pathophysiology, it would be useful to specifically study miR 
expression in the different structures of the aortic wall and in specific cell subsets. The use of 
laser capture microdissection which allows for the extraction of very precise tissue structures 
and cells 77 could be very useful in that purpose. This can be coupled with advanced flow 
cytometry-based cell sorting and RNA sequencing techniques to gain deeper insight into the 
expression profile and biological pathways altered in specific locations and specific cell types, 
both systemically and within the aneurysmal wall. 
Finally, the low level of consistency among the small clinical studies underlines the need to 
perform multicentre studies on larger cohorts of patients, providing enough power to detect a 
significant result after adjustment for multiple covariates and confounding factors. In this 
regard, longitudinal studies would be a great asset to investigate miR variation, roles and 
implications during disease progression. It could offer the opportunity to explore miRs as 
biomarkers of progression and risk of rupture, but also as biomarkers of therapeutic outcome.  
 
Conclusion 
Human and animal studies show that distinct miRs are differentially expressed within the 
aneurysmal wall (Figure 1) and may play causal roles in AAA formation (Figure 2). Basic 
experimental and translational approaches present advantages and limitations, but may 
complement each other. Human studies offer the possibility of identifying selective miRs as 
potential biomarkers and players in AAA pathophysiology. However, the investigation of 
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their precise roles may be limited and impacted by several confounding factors. Hence, the 
need to standardize study design and methods used, at least for miR analysis. Animals are 
more suitable to mechanistic studies and interventional approaches, which should allow for a 
better comprehension of the precise roles of miRs in AAA pathophysiology. There is an 
immense need to develop better animal models that more closely reproduce the human 
pathophysiological features of AAA. New models of the disease have been developed over 
the past few years 53, some of which have led to a reconsideration of the role of major 
pathways in disease pathogenesis 78. However, we believe that the current models are highly 
perfectible and research should still be directed towards this aim. Graft implantation in 
rodents as well as coated stent technology are under development and would offer new 
opportunities to test therapeutic strategies based on miR modulation. No doubt that major 
advances in the understanding of miR functions and regulations are to be expected and could 
offer innovative perspectives to identify, treat and improve the daily management of patients 
with AAA. 
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 Population 
 
Samples Main miRs identified Reference 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
AAA 
Screening study 
- 5 patients with infrarenal AAA undergoing 
elective surgical repair 
- 5 controls from cadaveric donors 
 
Validation study 
- 36 patients with AAA undergoing surgical 
repair (25 elective, 11 ruptured) 
- 7 controls from cadaveric donors 
 
Aorta: full thickness 
aortic wall 
- Differential miR expression between patients 
with AAA and controls: 
 Decreased: miR-133b, 133a, 331-3p, 30c-
2*, 204 
 
Pahl et al, 
2012 16 
- 15 patients with infrarenal large AAA (59 to 
68 mm) undergoing surgical repair 
- 5 controls from organ donors 
 
Aorta: full thickness 
aortic wall 
- Differential miR expression between patients 
with AAA and controls : 
 Decreased: miR-29b 
Maegdefess
el et al, 
2012 18 
- 13 patients with large AAA (57 to 68 mm) 
undergoing surgical repair (8 active smokers, 5 
non-smokers) 
- 5 controls from organ donors 
 
Aorta: full thickness 
aortic wall 
- Differential miR expression between patients 
with AAA and controls : 
 Increased: miR-21 
Maegdefess
el et al, 
2012 13 
- 5 patients with AAA who underwent surgery 
- 4 controls from patients without AAA 
 
Aorta: formalin-fixed 
paraffin-embedded 
sections 
- Differential miR expression between patients 
with AAA and controls : 
 Increased: miR-205, 21, 133b, 378 
Kim et al,  
2014 14 
Screening study 
- 6 patients with AAA undergoing surgical 
open repair 
- 6 patients from men undergoing liver 
transplantation 
 
Validation study 
- 10 patients with AAA undergoing surgical 
open repair (6 elective AAA, 4 ruptured AAA) 
- 10 controls 
 
Aorta: medial wall 
dissected from luminal 
thrombus and adventitia, 
culture of vascular 
smooth muscle cells 
(VSMCs) 
- Differential miR expression between patients 
with AAA and controls: 
 Increased: miR-516a-5p 
 Decreased: miR-1260 
  
Cheuk et al, 
2014 23 
- 10 patients with large infrarenal AAA 
(>50mm) undergoing surgical open repair 
 
 
 
 
Aorta: full thickness of 
the aortic wall 
- Body biopsy: at the site 
of maximum AAA 
dilatation 
- Neck biopsy: at the site 
of macroscopically non-
dilated AAA neck 
- miRs found exclusively in AAA body: miR-
96, 9, 105, 33 
- miRs found exclusively in AAA neck: miR-
189, 151, 154, 154*, 153, 188, 147, 183, 199b 
- Differential miR expression between AAA 
body and AAA neck:  
 Increased: miR-155, 28, 30a-3p, 150, 302b*, 
93, 99a 
 
Biros et al, 
2014 19 
- 10 patients with large infrarenal AAA 
(>50mm) undergoing surgical open repair 
- 10 patients with peripheral arterial disease 
(PAD) as controls 
Serum - miRs found exclusively in patients with AAA, 
not in controls : miR-220, 10a, 23b 
- Differential miR level between patients with 
AAA and patients with PAD:  
 Increased: miR-155 
 
Initial study 
- 19 patients with infrarenal AAA undergoing 
surgical open repair 
- 10 controls from cadaveric donors 
 
Validation study 
- 22 patients with AAA infrarenal undergoing 
surgical open repair  
- 17 controls from cadaveric donors 
- 3 patients with aorto-occlusive disease 
 
Aorta: full thickness of 
the aortic wall 
- No significant difference observed between 
patients with AAA and controls 
Stather et al, 
2015 25 
Initial study 
- 15 patients with large AAA (>54mm) 
- 10 healthy controls 
 
Validation study 
- 40 patients with small AAA (30-54mm) 
Whole blood - Differential miR level between patients with 
AAA and controls: 
 Decreased: miR-15a, 196b 
- Differential miR level between patients with 
PAD and controls: 
 Decreased: miR-let-7e, 15a, 196b 
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- 40 patients with  large AAA (>54mm) 
- 40 patients with AAA who had surgical repair 
(samples collected 6 months after open or 
endovascular repair) 
- 40 patients with PAD 
- 40 healthy controls 
 
 Increased: miR-411 
           
- 36 patients with small AAA (30-54mm) 
- 36 patients with  large AAA (>54mm) 
- 35 patients who had AAA repair (samples 
collected 6 months after open or endovascular 
repair) 
- 35 patients with PAD 
- 28 healthy controls 
 
Plasma 
 
- Differential miR level between patients with 
AAA and controls: 
 Decreased: miR-196b but significance not 
maintained after binary logistic regression 
 
- 20 patients with infrarenal AAA undergoing 
surgical open repair 
- 14 controls from organ donors 
 
Aorta: whole tissue or 
extraction of areas rich in 
adventitial tertiary 
lymphoid organs 
(ATLOs) 
 
- Differential miR expression in ATLOs 
compared to VSMCs from non-aneurysmal 
aorta: 
 Increased: 489-3p  
 Decreased:  miR-15a-3p, 30a-5p 
 
Spear et al, 
2015 20 
- 24 patients with AAA requiring surgery (> 50 
mm or increasing more than 10 mm during the 
past 6 months),     
- 18 patients with PAD 
 
Plasma - Differential miR level between patients with 
AAA and patients with PAD: 
 Decreased: miR-15a-3p, 30a-5p 
- 22 patients with infrarenal large AAA (52 to 
115 mm) undergoing elective surgical open 
repair 
- 14 controls from organ donors 
Aorta: full thickness 
aortic wall 
- Differential miR expression between patients 
with AAA and controls : 
 Decreased: miR-24, 27b 
 
Maegdefess
el et al, 
2014 17 
- 54 patients with small AAA (45-67 mm) 
- 51 patients with large AAA (69-150 mm) 
- 22 patients with peripheral vascular occlusive 
disease (PVOD) 
- 52  controls 
 
Plasma - Differential miR level between patients with 
AAA and controls: 
 Decreased: miR-24 
- Differential miR level between patients with 
AAA and patients with PVOD: 
 Decreased: miR-24 
- 13 patients with infrarenal AAA undergoing 
elective surgical open repair 
- 7 controls from ascending normal aorta from 
patients undergoing aortic valve replacement 
surgery 
 
Aorta: full thickness 
aortic wall 
- Differential miR expression between patients 
with AAA and controls : 
 Increased: miR-126, 20a, 27a, 92a, 221, 222, 
let-7f, 21, 155, 146a, 223, 124a, 29b 
Kin et al, 
2012 15 
- 23 patients with AAA  
- 17 patients with coronary artery disease 
(CAD) 
- 12 healthy volunteers 
 
Plasma - Differential miR level between AAA and 
controls: 
 Decreased: miR-124a, 29b, 155, 223, 126, 
146a 
- Differential miR expression in plasma 
between AAA and CAD: 
 Decreased:  miR-124a, 29b, 155, 223, 21 
Screening study 
- 10 patients with  AAA  
- 10 healthy controls 
 
Validation study 
- 60 patients with  AAA  
- 60 healthy controls 
 
Plasma - Differential miR level between patients with 
AAA and controls:  
 Increased: miR-191-3p, 455-3p, 1281 
 
Zhang et al, 
2015 26 
- 32 patients with AAA 
- 41 controls 
Plasma - Inverse association of miR level with the 
presence of AAA and the aortic diameter: miR-
195 
Zampetaki 
et al, 2015 
27 
 
TAA 
- 30 patients with ascending TAA + tricuspid 
aortic valves (TAV) undergoing surgery 
- 10 controls from ascending non aneurysmal 
aorta of heart donors and coronary artery 
bypass graft patients 
Aorta: full thickness 
aortic wall 
- Differential miR expression between patients 
with TAA + TAV and controls : 
 Decreased: miRs -1, 21, 29a, 133a, 486-5p 
Jones et al, 
2011  40 
- 10 patients with ascending TAA + tricuspid 
aortic valves (TAV) undergoing surgery 
Aorta: full thickness 
aortic wall 
- Differential miR expression between patients 
with TAA + TAV and controls : 
Pei et al, 
2015 44 
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- 10 controls patients from non-aneurysmal 
aortas of coronary artery bypass graft patients 
 Increased: miR-145 
 
- 10 patients with non-familial non syndromic 
ascending TAA undergoing surgery 
- 10 controls from ascending non aneurysmal 
aorta of heart transplant recipients  
Aorta: full thickness 
aortic wall 
- Differential miR expression between patients 
with TAA and controls : 
 99 differentially expressed miRs identified 
by microarray 
 
Patuzzo et 
al, 2012 42 
- 79 patients with TAA + bicuspid aortic valve 
(BAV) undergoing surgery 
- 30 patients with TAA + tricuspid aortic valve 
(TAV) undergoing surgery 
- 33 controls from non-aneurysmal aorta of 
coronary bypass surgery patients 
- Aorta: full thickness 
aortic wall 
- Differential miR expression between patients 
with TAA + BAV, with TAA + TAV and 
controls : 
 Increased: miR-29b 
 
Boon et al,  
2011 43 
- 21 patients with ascending TAA + bicuspid 
aortic valves (BAV) undergoing surgery 
- 21 patients with ascending TAA + tricuspid 
aortic valve (TAV) undergoing surgery 
- 10 controls from non-aneurysmal ascending 
aorta of heart transplant donors or recipients 
Aorta: full thickness 
aortic wall 
 
- Differential miR expression between patients 
with TAA + BAV and controls : 
 Decreased: miR-143 
 Increased: miR-29a, 145 
- Differential miR expression between patients 
with TAA + TAV and controls : 
 Decreased: miR-1, 133a, 143 
 Increased: miR-21 
- Differential miR expression between patients 
with TAA + TAV and patients with TAA + 
BAV 
 Decreased: miR-1 
 Increased: miR-21 
 
Ikonomidis 
et al, 2013 
41 
Plasma - Differential miR level between patients with 
TAA + BAV and controls : 
 Decreased: miR-145 
 Increased: miR-133a 
- Differential miR expression between patients 
with TAA + TAV and controls : 
 Decreased: miR-21, 29a, 143 
 Increased: 133a 
 
 
Table 1: Summary of human studies on miRs in aortic aneurysms. 
Legends: AAA: abdominal aortic aneurysm 
               BAV: bicuspid aortic valves 
               CAD: coronary artery disease  
               PAD: peripheral arterial disease 
               PVOD: peripheral vascular occlusive disease  
               TAA: thoracic aortic aneurysm 
               TAV: tricuspid aortic valves 
               VSMCs: vascular smooth muscle cells 
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 Animal models Main miRs dysregulated in animal models  
validated by qPCR 
 
miRs observed in animal models also dysregulated 
in patients with aortic aneurysm 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
AAA 
Angiotensin II 
infusion in apoE-/- 
mice 
- Differential miR expression between aneurysmal whole 
aortic tissue and controls:  
 Increased: 
13: miR-21 
27: miR-195 
 Decreased:  
18: miR-29b 
17: miR-24 
54: miR-26a 
 
- Differential miR expression between endothelium of 
aneurysmal aorta and controls:  
 Increased: 
14: miR-21, 1, 133b, 207, 378, 1957, 712, 205 
 Decreased:  
14:  miR-1952, 1249 
 
- Differential miR expression in plasma between mice 
with AAA and controls:   
 Decreased:  
17: miR-24 
 
- Differential miR expression between abdominal 
aneurysmal whole aortic tissue and controls:  
 Increased: 
13: miR-21 
15: miR-21, 146a, 29b, 221, 222 
14: miR-21, 133b 
 Decreased:  
18: miR-29b 
17: miR-24 
16: miR-133b 
 
- Differential miR level in plasma between patients 
with AAA and controls:   
 Decreased:  
17: miR-24 
27: miR-195 
15: miR-29b 
 
 
- Differential miR level in plasma between patients 
with AAA and coronary artery disease:   
 Decreased:  
15: miR-29b 
 
 
Angiotensin II 
infusion in C57BL/6 
mice 
Differential miR expression between aneurysmal whole 
aortic tissue and controls:  
 Increased:  
43: miR-29b 
 
Elastase perfusion 
in ApoE-/- mice 
Differential miR expression between aneurysmal whole 
aortic tissue and controls:  
 Increased: 
54: miR-21 
 Decreased:  
54: miR-26a 
 
Elastase perfusion in 
C57BL/6 mice 
Differential miR expression between aneurysmal whole 
aortic tissue and controls:  
 Increased: 
13: miR-21 
 Decreased:  
18: miR-29b 
17: miR-24 
 
- Differential miR level in plasma between mice with 
AAA and controls:   
 Decreased:  
17: miR-24 
 
Calcium chloride and 
collagenase 
application in 
Sprague-Dawley rats 
Differential miR expression between aneurysmal whole 
aortic tissue and controls:  
 Increased:  
59: miR-19a, 19b,132, 221 
 
 
 
 
 
TAA 
Fibulin-4(R/R) 
knockdown mice 
Differential miR expression between aneurysmal aortic 
tissue and controls: 39-44, 68 
 Increased: miR-29a, 29b, 29c 43 
 
-  Differential miR expression between aneurysmal 
whole aortic tissue (from patients with TAA + BAV) 
and controls:  
 Increased: miR-29a 41  
 
- Differential miR expression between patients with 
TAA and controls : 
 Increased: miR-29b 42  
Fbn1(C1039G/+) 
mice 
 Differential miR expression between aneurysmal whole 
aortic tissue and controls:  
 Increased: miR-29b 68 
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  Table 2: Main miRs identified in animal models of aortic aneurysms and comparison with miRs.    
  dysregulated in human 
  Legends: AAA: abdominal aortic aneurysm 
                  BAV: bicuspid aortic valve 
                  ApoE-/-: apolipoprotein E deficient mice 
                  qPCR: quantitative polymerase chain reaction 
                  TAA: thoracic aortic aneurysm 
                  TAV: tricuspid aortic valve 
     
 
  
 
     Figure 1: Main miRs identified in aortic structures during AAA. 
     Legends: AAA: abdominal aortic aneurysm 
                    ATLOs : adventitial tertiary lymphoid organs 
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                    VSMCs: vascular smooth muscle cells 
 
 
  
 
 
                    
           
                  
   Figure 2: Implication of miRs in pathogenic pathways of AAA. 
.            
   Legends: AAA: abdominal aortic aneurysm 
                  Chi3l1: chitinase 3-like 1 
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                  COL1A1: collagen type 1, alpha 1 
                  COL3A1: collagen type 3, alpha 1 
                  COL5A1: collagen type 5, alpha 1 
                  CTLA4: cytotoxic T-lymphocyte-associated protein 
                  ECM: extracellular matrix  
                  IL-3: interleukin-3 
                  MCP-1: monocyte chemoattractant protein-1 
                  MMP: metalloproteinase 
                  PTEN: phosphatase and tensin homolog 
                  RECK: reversion-inducing cysteine-rich protein with kazal motifs 
                  TGF beta: transforming growth factor beta 
                  Th2: T helper lymphocyte, type 2 
                  TIMP3: tissue inhibitor of metalloproteinase 3 
                  TNF alpha: tumor necrosis factor alpha 
                  VEGFA: vascular endothelial growth factor A 
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 Population 
 
Samples Main miRs identified Reference 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
AAA 
Screening study 
- 5 patients with infrarenal AAA undergoing 
elective surgical repair 
- 5 controls from cadaveric donors 
 
Validation study 
- 36 patients with AAA undergoing surgical 
repair (25 elective, 11 ruptured) 
- 7 controls from cadaveric donors 
 
Aorta: full thickness 
aortic wall 
- Differential miR expression between patients 
with AAA and controls: 
 Decreased: miR-133b, 133a, 331-3p, 30c-
2*, 204 
 
Pahl et al, 
2012 16 
- 15 patients with infrarenal large AAA (59 to 
68 mm) undergoing surgical repair 
- 5 controls from organ donors 
 
Aorta: full thickness 
aortic wall 
- Differential miR expression between patients 
with AAA and controls : 
 Decreased: miR-29b 
Maegdefess
el et al, 
2012 18 
- 13 patients with large AAA (57 to 68 mm) 
undergoing surgical repair (8 active smokers, 5 
non-smokers) 
- 5 controls from organ donors 
 
Aorta: full thickness 
aortic wall 
- Differential miR expression between patients 
with AAA and controls : 
 Increased: miR-21 
Maegdefess
el et al, 
2012 13 
- 5 patients with AAA who underwent surgery 
- 4 controls from patients without AAA 
 
Aorta: formalin-fixed 
paraffin-embedded 
sections 
- Differential miR expression between patients 
with AAA and controls : 
 Increased: miR-205, 21, 133b, 378 
Kim et al,  
2014 14 
Screening study 
- 6 patients with AAA undergoing surgical 
open repair 
- 6 patients from men undergoing liver 
transplantation 
 
Validation study 
- 10 patients with AAA undergoing surgical 
open repair (6 elective AAA, 4 ruptured AAA) 
- 10 controls 
 
Aorta: medial wall 
dissected from luminal 
thrombus and adventitia, 
culture of vascular 
smooth muscle cells 
(VSMCs) 
- Differential miR expression between patients 
with AAA and controls: 
 Increased: miR-516a-5p 
 Decreased: miR-1260 
  
Cheuk et al, 
2014 23 
- 10 patients with large infrarenal AAA 
(>50mm) undergoing surgical open repair 
 
 
 
 
Aorta: full thickness of 
the aortic wall 
- Body biopsy: at the site 
of maximum AAA 
dilatation 
- Neck biopsy: at the site 
of macroscopically non-
dilated AAA neck 
- miRs found exclusively in AAA body: miR-
96, 9, 105, 33 
- miRs found exclusively in AAA neck: miR-
189, 151, 154, 154*, 153, 188, 147, 183, 199b 
- Differential miR expression between AAA 
body and AAA neck:  
 Increased: miR-155, 28, 30a-3p, 150, 302b*, 
93, 99a 
 
Biros et al, 
2014 19 
- 10 patients with large infrarenal AAA 
(>50mm) undergoing surgical open repair 
- 10 patients with peripheral arterial disease 
(PAD) as controls 
Serum - miRs found exclusively in patients with AAA, 
not in controls : miR-220, 10a, 23b 
- Differential miR level between patients with 
AAA and patients with PAD:  
 Increased: miR-155 
 
Initial study 
- 19 patients with infrarenal AAA undergoing 
surgical open repair 
- 10 controls from cadaveric donors 
 
Validation study 
- 22 patients with AAA infrarenal undergoing 
surgical open repair  
- 17 controls from cadaveric donors 
- 3 patients with aorto-occlusive disease 
 
Aorta: full thickness of 
the aortic wall 
- No significant difference observed between 
patients with AAA and controls 
Stather et al, 
2015 25 
Initial study 
- 15 patients with large AAA (>54mm) 
- 10 healthy controls 
 
Validation study 
- 40 patients with small AAA (30-54mm) 
Whole blood - Differential miR level between patients with 
AAA and controls: 
 Decreased: miR-15a, 196b 
- Differential miR level between patients with 
PAD and controls: 
 Decreased: miR-let-7e, 15a, 196b 
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- 40 patients with  large AAA (>54mm) 
- 40 patients with AAA who had surgical repair 
(samples collected 6 months after open or 
endovascular repair) 
- 40 patients with PAD 
- 40 healthy controls 
 
 Increased: miR-411 
           
- 36 patients with small AAA (30-54mm) 
- 36 patients with  large AAA (>54mm) 
- 35 patients who had AAA repair (samples 
collected 6 months after open or endovascular 
repair) 
- 35 patients with PAD 
- 28 healthy controls 
 
Plasma 
 
- Differential miR level between patients with 
AAA and controls: 
 Decreased: miR-196b but significance not 
maintained after binary logistic regression 
 
- 20 patients with infrarenal AAA undergoing 
surgical open repair 
- 14 controls from organ donors 
 
Aorta: whole tissue or 
extraction of areas rich in 
adventitial tertiary 
lymphoid organs 
(ATLOs) 
 
- Differential miR expression in ATLOs 
compared to VSMCs from non-aneurysmal 
aorta: 
 Increased: 489-3p  
 Decreased:  miR-15a-3p, 30a-5p 
 
Spear et al, 
2015 20 
- 24 patients with AAA requiring surgery (> 50 
mm or increasing more than 10 mm during the 
past 6 months),     
- 18 patients with PAD 
 
Plasma - Differential miR level between patients with 
AAA and patients with PAD: 
 Decreased: miR-15a-3p, 30a-5p 
- 22 patients with infrarenal large AAA (52 to 
115 mm) undergoing elective surgical open 
repair 
- 14 controls from organ donors 
Aorta: full thickness 
aortic wall 
- Differential miR expression between patients 
with AAA and controls : 
 Decreased: miR-24, 27b 
 
Maegdefess
el et al, 
2014 17 
- 54 patients with small AAA (45-67 mm) 
- 51 patients with large AAA (69-150 mm) 
- 22 patients with peripheral vascular occlusive 
disease (PVOD) 
- 52  controls 
 
Plasma - Differential miR level between patients with 
AAA and controls: 
 Decreased: miR-24 
- Differential miR level between patients with 
AAA and patients with PVOD: 
 Decreased: miR-24 
- 13 patients with infrarenal AAA undergoing 
elective surgical open repair 
- 7 controls from ascending normal aorta from 
patients undergoing aortic valve replacement 
surgery 
 
Aorta: full thickness 
aortic wall 
- Differential miR expression between patients 
with AAA and controls : 
 Increased: miR-126, 20a, 27a, 92a, 221, 222, 
let-7f, 21, 155, 146a, 223, 124a, 29b 
Kin et al, 
2012 15 
- 23 patients with AAA  
- 17 patients with coronary artery disease 
(CAD) 
- 12 healthy volunteers 
 
Plasma - Differential miR level between AAA and 
controls: 
 Decreased: miR-124a, 29b, 155, 223, 126, 
146a 
- Differential miR expression in plasma 
between AAA and CAD: 
 Decreased:  miR-124a, 29b, 155, 223, 21 
Screening study 
- 10 patients with  AAA  
- 10 healthy controls 
 
Validation study 
- 60 patients with  AAA  
- 60 healthy controls 
 
Plasma - Differential miR level between patients with 
AAA and controls:  
 Increased: miR-191-3p, 455-3p, 1281 
 
Zhang et al, 
2015 26 
- 32 patients with AAA 
- 41 controls 
Plasma - Inverse association of miR level with the 
presence of AAA and the aortic diameter: miR-
195 
Zampetaki 
et al, 2015 
27 
 
TAA 
- 30 patients with ascending TAA + tricuspid 
aortic valves (TAV) undergoing surgery 
- 10 controls from ascending non aneurysmal 
aorta of heart donors and coronary artery 
bypass graft patients 
Aorta: full thickness 
aortic wall 
- Differential miR expression between patients 
with TAA + TAV and controls : 
 Decreased: miRs -1, 21, 29a, 133a, 486-5p 
Jones et al, 
2011  40 
- 10 patients with ascending TAA + tricuspid 
aortic valves (TAV) undergoing surgery 
Aorta: full thickness 
aortic wall 
- Differential miR expression between patients 
with TAA + TAV and controls : 
Pei et al, 
2015 44 
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- 10 controls patients from non-aneurysmal 
aortas of coronary artery bypass graft patients 
 Increased: miR-145 
 
- 10 patients with non-familial non syndromic 
ascending TAA undergoing surgery 
- 10 controls from ascending non aneurysmal 
aorta of heart transplant recipients  
Aorta: full thickness 
aortic wall 
- Differential miR expression between patients 
with TAA and controls : 
 99 differentially expressed miRs identified 
by microarray 
 
Patuzzo et 
al, 2012 42 
- 79 patients with TAA + bicuspid aortic valve 
(BAV) undergoing surgery 
- 30 patients with TAA + tricuspid aortic valve 
(TAV) undergoing surgery 
- 33 controls from non-aneurysmal aorta of 
coronary bypass surgery patients 
- Aorta: full thickness 
aortic wall 
- Differential miR expression between patients 
with TAA + BAV, with TAA + TAV and 
controls : 
 Increased: miR-29b 
 
Boon et al,  
2011 43 
- 21 patients with ascending TAA + bicuspid 
aortic valves (BAV) undergoing surgery 
- 21 patients with ascending TAA + tricuspid 
aortic valve (TAV) undergoing surgery 
- 10 controls from non-aneurysmal ascending 
aorta of heart transplant donors or recipients 
Aorta: full thickness 
aortic wall 
 
- Differential miR expression between patients 
with TAA + BAV and controls : 
 Decreased: miR-143 
 Increased: miR-29a, 145 
- Differential miR expression between patients 
with TAA + TAV and controls : 
 Decreased: miR-1, 133a, 143 
 Increased: miR-21 
- Differential miR expression between patients 
with TAA + TAV and patients with TAA + 
BAV 
 Decreased: miR-1 
 Increased: miR-21 
 
Ikonomidis 
et al, 2013 
41 
Plasma - Differential miR level between patients with 
TAA + BAV and controls : 
 Decreased: miR-145 
 Increased: miR-133a 
- Differential miR expression between patients 
with TAA + TAV and controls : 
 Decreased: miR-21, 29a, 143 
 Increased: 133a 
 
 
Table 1: Summary of human studies on miRs in aortic aneurysms. 
Legends: AAA: abdominal aortic aneurysm 
               BAV: bicuspid aortic valves 
               CAD: coronary artery disease  
               PAD: peripheral arterial disease 
               PVOD: peripheral vascular occlusive disease  
               TAA: thoracic aortic aneurysm 
               TAV: tricuspid aortic valves 
               VSMCs: vascular smooth muscle cells 
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 Animal models Main miRs dysregulated in animal models  
validated by qPCR 
 
miRs observed in animal models also dysregulated 
in patients with aortic aneurysm 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
AAA 
Angiotensin II 
infusion in apoE-/- 
mice 
- Differential miR expression between aneurysmal whole 
aortic tissue and controls:  
 Increased: 
13: miR-21 
27: miR-195 
 Decreased:  
18: miR-29b 
17: miR-24 
54: miR-26a 
 
- Differential miR expression between endothelium of 
aneurysmal aorta and controls:  
 Increased: 
14: miR-21, 1, 133b, 207, 378, 1957, 712, 205 
 Decreased:  
14:  miR-1952, 1249 
 
- Differential miR expression in plasma between mice 
with AAA and controls:   
 Decreased:  
17: miR-24 
 
- Differential miR expression between abdominal 
aneurysmal whole aortic tissue and controls:  
 Increased: 
13: miR-21 
15: miR-21, 146a, 29b, 221, 222 
14: miR-21, 133b 
 Decreased:  
18: miR-29b 
17: miR-24 
16: miR-133b 
 
- Differential miR level in plasma between patients 
with AAA and controls:   
 Decreased:  
17: miR-24 
27: miR-195 
15: miR-29b 
 
 
- Differential miR level in plasma between patients 
with AAA and coronary artery disease:   
 Decreased:  
15: miR-29b 
 
 
Angiotensin II 
infusion in C57BL/6 
mice 
Differential miR expression between aneurysmal whole 
aortic tissue and controls:  
 Increased:  
43: miR-29b 
 
Elastase perfusion 
in ApoE-/- mice 
Differential miR expression between aneurysmal whole 
aortic tissue and controls:  
 Increased: 
54: miR-21 
 Decreased:  
54: miR-26a 
 
Elastase perfusion in 
C57BL/6 mice 
Differential miR expression between aneurysmal whole 
aortic tissue and controls:  
 Increased: 
13: miR-21 
 Decreased:  
18: miR-29b 
17: miR-24 
 
- Differential miR level in plasma between mice with 
AAA and controls:   
 Decreased:  
17: miR-24 
 
Calcium chloride and 
collagenase 
application in 
Sprague-Dawley rats 
Differential miR expression between aneurysmal whole 
aortic tissue and controls:  
 Increased:  
59: miR-19a, 19b,132, 221 
 
 
 
 
 
TAA 
Fibulin-4(R/R) 
knockdown mice 
Differential miR expression between aneurysmal aortic 
tissue and controls: 39-44, 68 
 Increased: miR-29a, 29b, 29c 43 
 
-  Differential miR expression between aneurysmal 
whole aortic tissue (from patients with TAA + BAV) 
and controls:  
 Increased: miR-29a 41  
 
- Differential miR expression between patients with 
TAA and controls : 
 Increased: miR-29b 42  
Fbn1(C1039G/+) 
mice 
 Differential miR expression between aneurysmal whole 
aortic tissue and controls:  
 Increased: miR-29b 68 
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  Table 2: Main miRs identified in animal models of aortic aneurysms and comparison with miRs.    
  dysregulated in human 
  Legends: AAA: abdominal aortic aneurysm 
                  BAV: bicuspid aortic valve 
                  ApoE-/-: apolipoprotein E deficient mice 
                  qPCR: quantitative polymerase chain reaction 
                  TAA: thoracic aortic aneurysm 
                  TAV: tricuspid aortic valve 
     
 
miRs	  iden)ﬁed	  in	  ATLOs	  
-­‐	  Human:	  miR-­‐15a-­‐3p,	  30a-­‐5p,	  489-­‐3p	  
miRs	  deregulated	  in	  VSMCs	  from	  
aneurysmal	  )ssue	  
-­‐	  Human:	  miR-­‐516a-­‐5p,	  1260	  
miRs	  deregulated	  in	  endothelium	  
of	  aneurysmal	  aorta	  
-­‐	  Animal:	  miR-­‐1,	  21,	  133b,	  205,	  207,	  378,	  
712,	  1249,	  1952,	  1957	  
miRs	  deregulated	  in	  whole	  aneurysmal	  	  
aor)c	  )ssue	  
-­‐	  Human:	  miR-­‐20a,	  21,	  24,	  27a,	  27b,	  28,	  29b,	  
30a-­‐3p,	  30c-­‐2*,	  92a,	  93,	  99a,	  124a,	  126,	  133a,	  
133b,	  146a,	  150,	  155,	  204,	  205,	  221,	  222,	  223,	  
302b*,	  331-­‐3p,	  378,	  let-­‐7f	  
-­‐	  	  Animal:	  miR-­‐19a,	  19b,	  21,	  24,	  26a,	  29b,	  132,	  
195,	  221	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